Tumor mutation burden (TMB) evaluation discloses that PIK3CA amplified cervical cancers show less frequently than non-amplified cancers a low TMB of less than 80 (33.3% versus 47.5%), while amplified cancers have a higher prevalence of intermediate TMB of 80 to 180 (Figure 6). Here, PIK3CA is linked to cervical carcinoma.